Chirurgische und internistische Diagnostik und Therapie des Ösophaguskarzinoms – Update

Kernaussagen

Ätiologie und Epidemiologie

• Die Hauptrisikofaktoren für Plattenepithelkarzinome des Ösophagus sind Alkohol und Rauchen. Adenokarzinome entwickeln sich fast ausschließlich in einer Zylinderepithelmetaplasie der distalen Speiseröhre, meist als Folge einer chronischen gastroösophagealen Refluxkrankheit.

• Das Barrett-Karzinom ist zurzeit der Tumor mit der höchsten Zuwachsrate aller Malignome, die Inzidenz des Plattenepithelkarzinoms ist gleichbleibend.

Klinik und Diagnostik

• Eine eindeutige Dysphagie – Leitsymptom des Ösophaguskarzinoms – tritt meist erst in einem fortgeschrittenen Tumorstadium auf.

• Der Ausschluss/Nachweis von Fernmetastasen mittels CT von Hals/Thorax und Abdomen ist für die Therapieentscheidung eine der wichtigsten Staginguntersuchungen.

• Die genaueste Untersuchung für die Vorhersage der T-Klassifikation ist die Endosonografie, während die Unterscheidung von Mukosa- und Submukosainfiltration am ehesten endoskopisch gelingt („Lifting Sign“).

Therapie

• Bei Mukosakarzinomen umschriebenen Ausmaßes von < 2 cm und Ausschluss von Multifokalität ist bei Erfüllung aller erforderlichen Kriterien die endoskopische Resektion indiziert.

• Funktionell operable Patienten mit Submukosa- oder T2-Karzinom ohne Fernmetastasen werden primär einer radikalen Ösophagektomie zugeführt, wobei in den meisten Fällen die subtotale En-bloc-Ösophagektomie mit 2-Feld-Lymphadenektomie und hoch intrathorakaler Ösophagogastrostomie das Verfahren der Wahl ist.

• Bei funktionell operablen Patienten mit T3 – und resektablen T4-Karzinomen wird zur Verbesserung der Ausgangssituation für eine R0-Resektion die neoadjuvante Radiochemotherapie oder Chemotherapie (Adenokarzinome) vorangestellt.

• Funktionell inoperable Patienten sollten einer definitiven Radiochemotherapie zugeführt werden. Bei metastasierter Erkrankung kann eine Cisplatin-basierte Kombinationschemotherapie erfolgen.

• Literatur

• 1 Lagergren JL, Bergstrom R, Lindgren A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831
• 2 Leers JM, Bollschweiler E, Hölscher AH. Refluxanamnese von Patienten mit Adenokarzinom der Speiseröhre. Z Gastroenterol 2005; 43: 275-280
• 3 Bollschweiler E, Wolfgarten E, Gutschow C et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92: 549-555
• 4 Siewert JR, Hölscher AH, Becker K et al. Kardiakarzinom. Versuch einer therapeutisch relevanten Klassifikation. Chirurg 1987; 58: 25-32
• 5 Camargo MC, Anderson WF, King JB et al. Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut 2011; 60: 1644-1649
• 6 Bollschweiler E, Leers J, Hölscher AH. Epidemiologie des Ösophagus- und Magenkarzinoms. Gastroenterologe 2009; 4: 193-201
• 7 Bollschweiler E, Schröder W, Hölscher AH et al. Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus. Brit J Surg 2000; 87: 1106-1110
• 8 Wittekind CH, Greene FL, Henson DE et al. TNM-Supplement UICC. 3rd. ed. New York: Wiley & Liss; 2003
• 9 Wittekind Ch, Meyer HJ Hrsg. TNM Klassifikation maligner Tumoren. 7.. Aufl. Weinheim: Wiley-VCH; 2010
• 10 Gertler R, Stein HJ, Langer R et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg 2011; 253: 689-698
• 11 Bollschweiler E, Baldus SE, Schröder W et al. High rate of lymph node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy 2006; 38: 144-151
• 12 Liu L, Hofstetter WL, Rashid A et al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive esophageal adenocarcinoma. Am J Surg Pathol 2005; 29: 1079-1085
• 13 Westerterp M, Koppert LB, Buskens CJ et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virch Arch 2005; 446: 497-504
• 14 Hölscher AH, Bollschweiler E, Schröder W et al. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg 2011; 254: 802-807 discussion 807-808
• 15 Hölscher AH. Adenocarcinoma of the Cardia. In: Patterson GA, Pearson GF, Cooper JD, et al. eds. Pearson’s Thoracic and Esophageal Surgery. 3rd. ed. Philadelphia: Churchill Livingstone; 2008: 492-497
• 16 Flamen P, Van Cutsem E, Lerut A et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002; 13: 361
• 17 Vallböhmer D, Hölscher AH, Dietlein M et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009; 250: 888-894
• 18 Hölscher AH, Fetzner UK, Bludau M et al. Complications and management of complications in oesophageal surgery. Zentralbl Chir 2011; 136: 213-223
• 19 May A, Gunter E, Roth F et al. Accuracy of staging in early esophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective and blinded trial. GUT 2004; 53: 634-640
• 20 Mönig SP, Schröder W, Baldus SE et al. Preoperative lymph node staging in gastrointestinal cancer – correlation between size and tumour stage. Onkologie 2002; 25: 342-344
• 21 Schröder W, Bollschweiler E, Kossow C et al. Preoperative risk analysis – a reliable predictor of postoperative outcome after transthoracic esophagectomy?. Langenbecks Arch Surg 2006; 391: 455-460
• 22 Ell C, May A, Gossner L et al. Kurative endoskopische Therapie früher Adenokarzinome der Speiseröhre. Dtsch Ärztebl 2003; 100: A1438-A1448
• 23 Pech O, Bollschweiler E, Manner H et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett’s esophagus at two high-volume centers. Ann Surg 2011; 254: 67-72
• 24 Hulscher JBF, Van Sandick JW, De Beure AGEM et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl Med 2002; 347: 1662-1669
• 25 Omloo JMT, Lagarde SM, Hulscher JBF et al. Extended transthoracic resection compared with limited transhiatal resection for adneocarcinoma of the mid/distal esophagus: five year survival of a randomized clinical trial. Ann Surg 2007; 246: 992-1000
• 26 Peyre C, Hagen J, De Meester S et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008; 248: 549-556
• 27 Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317
• 28 Gutschow C, Schröder W, Wolfgarten E et al. Operation nach Merendino mit Vaguserhaltung beim Frühkarzinom des gastroösophagealen Übergangs. Zentralbl Chir 2004; 129: 276-281
• 29 Schneider PM, Baldus SE, Metzger R et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer. Implications for response classification.. Ann Surg 2005; 242: 684-692
• 30 Bollschweiler E, Metzger R, Drebber U et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009; 20: 231-238
• 31 Vallböhmer D, Hölscher AH, DeMeester S et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypTONOMORO esophageal cancer. Ann Surg 2010; 252: 744-749
• 32 Sjoquist KM, Burmeister BH, Smithers BM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692
• 33 Gebski V, Burmeister B, Smithers B et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234
• 34 Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53: 925-930
• 35 Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002; 183: 274-279
• 36 Urschel JD, Vasan H. A meta-analysis of ranomised controlled trials that compared neoadjuavnt chemoradiation and surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-543
• 37 Malthaner R, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. The Cochrane Database of Systematic Reviews 2003; 4 CD001556.
• 38 Greer SE, Goodney PP, Sutton JE et al. Neoadjuvant chemoradiation for esophageal carcinoma: A meta-analysis. Surgery 2005; 137: 172-179
• 39 Soetikno RM, Gotoda T, Nakanishi Y et al. Endoscopic mucosal resection. Gastrointest Endosc 2003; 57: 567-579
• 40 Takahashi H, Arimura Y, Masao H et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc 2010; 72: 255-264
• 41 Farhat S, Chaussade S, Ponchon T et al. Endoscopic submucosal dissection in a European setting. A multi-institutional report of a technique in development. Endoscopy 2011; 43: 664-670
• 42 Vieth M, Ell C, Gossner L et al. Histological analysis of endoscopic resection specimens from 326 patients with Barrett’s esophagus and early neoplasia. Endoscopy 2004; 36: 776-781
• 43 Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003; 58: 183-188
• 44 Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009; 360: 2277-2288
• 45 Pech O, Ell C. Endoscopic therapy of Barrett’s esophagus. Curr Opin Gastroenterol 2009; 25: 405-411
• 46 Bergman JJ, Zhang YM, He S et al. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. Gastrointest Endosc 2011; 74: 1181-1190
• 47 van Vilsteren FG, Alvarez Herrero L, Pouw RE et al. Radiofrequency ablation for the endoscopic eradication of esophageal squamous high grade intraepithelial neoplasia and mucosal squamous cell carcinoma. Endoscopy 2011; 43: 282-290
• 48 Hölscher AH, Schröder W, Bollschweiler E et al. Wie sicher ist die hoch intrathorakale Ösophagogastrostomie?. Chirurg 2003; 74: 726-733
• 49 Hölscher AH, Schneider PM, Gutschow C et al. Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Am Surg 2007; 245: 241-246
• 50 Stein HJ, Feith M, Mueller J et al. Limited resection for early adenocarcinoma in Barrett’s esophagus. Ann Surg 2000; 232: 733-742
• 51 Leers JM, Schröder W, Vivaldi C et al. Präoperative Koloskopie vor Magenhochzug. Chirurg 2004; 75: 1210-1214
• 52 Luketich JD, Alvelo-Rivera M, Buenaventura PO et al. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 2003; 238: 486-494 discussion 494-495
• 53 Lazzarino AI, Nagpal K, Bottle A et al. Open versus minimally invasive esophagectomy: trends of utilization and associated outcomes in England. Ann Surg 2010; 252: 292-298
• 54 Nagpal K, Ahmed K, Vats A et al. Is minimally invasive surgery beneficial in the management of esophageal cancer? A meta-analysis.. Surg Endosc 2010; 24: 1621-1629
• 55 Stippel DL, Taylan C, Schroder W et al. Supraventricular tachyarrhythmia as early indicator of a complicated course after esophagectomy. Dis Esophagus 2005; 18: 267-273
• 56 Hölscher AH, Metzger R, Brabender J et al. High-volume centers – effect of case load on outcome in cancer surgery. Onkologie 2004; 27: 412-416
• 57 Hölscher AH, Bollschweiler E, Schneider PM et al. Prognosis of early esophageal cancer. Cancer 1995; 76: 178-186
• 58 Hölscher AH, Bollschweiler E, Bumm R et al. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery 1995; 118: 845-855
• 59 Prenzel KL, Bollschweiler E, Schröder W et al. Prognostic relevance of skip metastases in esophageal cancer. Ann Thorac Surg 2010; 90: 1662-1667
• 60 Bollschweiler E, Hölscher AH, Metzger R et al. Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg 2011; 92: 2020-2027
• 61 Nygaard K, Hagen S, Hansen HS et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer.. World J Surg 1992; 16: 1104-1109
• 62 Arnott SJ, Duncan W, Gignoux M et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2000; 4 DC001799
• 63 Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984
• 64 Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 2002; 359: 1727-1733
• 65 Ychou M, Boige V, Pignon JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721
• 66 Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction, J. Clin Oncol 2009; 27: 851-856
• 67 Abou-Jawde JM, Mekhail T, Adelstein DJ et al. Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer. Chest 2005; 128: 250-256
• 68 Blazeby JM, Sanford E, Falk SJ et al. Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer 2004; 103: 1791-1798
• 69 Khushalani NI, Leichman CG, Proulx G et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002; 20: 2844-2850
• 70 Lorenzen S, Brücher B, Zimmermann F et al. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer 2008; 99: 1020-1026
• 71 van der Gaast A, van Hagen P, Hulshof M et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study. Proc Am Soc Clin Oncol 2010; 28 (Suppl. 15) 4004 (abstract)
• 72 Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 2005; 63: 5-24
• 73 Ruol A, Rizzetto C, Castoro C et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?. Ann Surg 2010; 252: 788-796
• 74 Berger AC, Farma J, Scott WJ et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337
• 75 Bruecher BLDM, Becker K, Lordick F et al. The clinical impact of histopathological response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006; 106: 2119-2127
• 76 Langer R, Ott K, Feith M et al. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol 2009; 22: 1555-1563
• 77 Rizk NP, Venkatraman E, Bains MS. American Joint Committee on Cancer et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007; 25: 507-512
• 78 Swisher SG, Hofstetter W, Wu TT et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response following preoperative chemoradiation (CRT). Ann Surg 2005; 241: 810-820
• 79 Lightdale CJ, Kulkarni KG. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol 2005; 23: 4483-4490
• 80 Jones DR, Parker Jr LA, Detterbeck FC et al. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999; 85: 1026
• 81 Swisher SG, Maish M, Erasmus JJ et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004; 78: 1152-1157
• 82 Downey RJ, Akhurst T, Ilson D et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003; 21: 428
• 83 Weber WA, Ott K, Becker K et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065
• 84 Ott K, Weber WA, Lordick F et al. Metabolic imaging predicts response, survival and recurrence in adenocarcinomas of the esophagogastric junction (AEG) in a prospective trial. J Clin Oncol 2006; 24: 4692-4698
• 85 Lordick F, Ott K, Krause BJ et al. Use of PET to assess early metabolic response and guide treatment of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: a feasibility study. Lancet Oncol 2007; 8: 797-805
• 86 Kleinberg L, Gibson MK, Forastiere AA. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nat Clin Pract Oncol 2007; 4: 282-294
• 87 Minsky B, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1151-1153
• 88 Lordick F, Ebert M, Stein HJ. Current treatment approach to locally advanced esophageal cancer: Is resection mandatory?. Future Oncology 2006; 2: 717-721
• 89 Lorenzen S, Duyster J, Lersch C et al. Capecitabine plus docetaxel every three weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Brit J Cancer 2005; 92: 2129-2133
• 90 Lorenzen S, Schuster T, Porschen R et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009; 20: 1667-1673
• 91 Bleiberg H, Conroy T, Paillot B et al. Randomized phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced oesophageal cancer. Eur J Cancer 1997; 33: 1216-1220
• 92 Ilson DH, Saltz L, Enzinger P et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J of Clin Oncol 1999; 10: 3270-3275
• 93 Conroy T, Etienne PL, Adenis A et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol 2002; 13: 721-729